Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)

Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a percentage of patients with prolonged survival rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Linlin, Overholser, Jay, Good, Anthony J., Ede, Nicholas J., Kaumaya, Pravin T. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137037/
https://www.ncbi.nlm.nih.gov/pubmed/35646678
http://dx.doi.org/10.3389/fonc.2022.826566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137037/
https://www.ncbi.nlm.nih.gov/pubmed/35646678
http://dx.doi.org/10.3389/fonc.2022.826566

Ejemplares similares